Collegium Pharmaceutical (COLL) Accounts Payables (2014 - 2026)

Collegium Pharmaceutical's Accounts Payables history runs 13 years deep, the most recent figure standing at $6.8 million for Q1 2026.

• On a quarterly basis, Accounts Payables fell 61.75% year-over-year to $6.8 million in Q1 2026; TTM through Mar 2026 was $6.8 million, a 61.75% decrease from a year earlier, with the FY2025 full-year figure at $10.7 million, up 170.95% from the prior year.
• Accounts Payables slipped to $6.8 million in Q1 2026 per COLL's latest filing, from $10.7 million in the prior quarter.
• Across five years, Accounts Payables topped out at $17.9 million in Q1 2025 and bottomed at $2.4 million in Q2 2024.
• The 5-year median for Accounts Payables is $6.0 million (2024), against an average of $6.4 million.
• Across the five-year window, Accounts Payables tumbled 63.48% in 2023 and jumped 351.49% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $3.5 million in 2022, then surged by 148.77% to $8.7 million in 2023, then slumped by 54.74% to $3.9 million in 2024, then surged by 170.95% to $10.7 million in 2025, then sank by 35.94% to $6.8 million in 2026.
• Per Business Quant, the three latest COLL Accounts Payables figures stand at $6.8 million (Q1 2026), $10.7 million (Q4 2025), and $7.6 million (Q3 2025).